Search

Showing results for: AUTHOR - Seymour, JF

Found: 36 results

Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy Blood Adv - 2020-10-13 Davis, JE; Handunnetti, SM; Ludford-Menting, M; Sharpe, C; Blombery, P; Anderson, MA; Roberts, AW; Seymour, JF; Tam, CS; Ritchie, DS; Koldej, RM
Link to Open Access at Publisher's Site Download PDF
Tumor lysis syndrome: still the Achilles heel of venetoclax in treatment of CLL? Leukemia & Lymphoma - 2020-08-04 Anderson, MA; Seymour, JF
Link to Publisher's Version
Zanubrutinib for the treatment of patients with Waldenstrom macroglobulinemia: three years of follow-up Blood - 2020-07-22 Trotman, J; Opat, S; Gottlieb, DJ; Simpson, D; Marlton, P; Cull, G; Munoz, J; Tedeschi, A; Roberts, AW; Seymour, JF; Atwal, SK; Yu, Y; Novotny, W; Holmgren, EB; Tan, Z; Hilger, J; Huang, J; Tam, C
Link to Publisher's Version
BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax Blood - 2020-04-03 Lin, VS; Lew, TE; Handunnetti, SM; Blombery, P; Nguyen, T; Westerman, DA; Kuss, BJ; Tam, C; Roberts, AW; Seymour, JF; Anderson, MA
Link to Open Access at Publisher's Site
Multiple BCL2 mutations co-occurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax Blood - 2020-01-17 Blombery, P; Thompson, E; Nguyen, T; Birkinshaw, RW; Gong, J; Chen, X; McBean, M; Thijssen, R; Conway, T; Anderson, MA; Seymour, JF; Westerman, DA; Czabotar, PE; Huang, DCS; Roberts, AW
Link to Publisher's Version
Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months Blood Advances - 2020-01-14 Lew, TE; Anderson, MA; Lin, VS; Handunnetti, SM; Came, NA; Blombery, P; Westerman, DA; Wall, M; Tam, CS; Roberts, AW; Seymour, JF
Link to Open Access at Publisher's Site Download PDF
Phase 1 study of selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL Blood - 2019-07-24 Tam, CSL; Trotman, J; Opat, S; Burger, JA; Cull, G; Gottlieb, DJ; Harrup, RA; Johnston, P; Marlton, P; Munoz, J; Seymour, JF; Simpson, DR; Tedeschi, A; Elstrom, R; Yu, Y; Tang, Z; Han, L; Huang, J; Novotny, W; Wang, L; Roberts, AW
Link to Publisher's Version
Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables Blood - 2019-07 Roberts, AW; Ma, S; Kipps, TJ; Coutre, SE; Davids, MS; Eichhorst, B; Hallek, M; Byrd, JC; Humphrey, K; Zhou, L; Chyla, B; Nielsen, J; Potluri, J; Kim, SY; Verdugo, M; Stilgenbauer, S; Wierda, WG; Seymour, JF
Link to Publisher's Version
Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma British Journal of Haematology - 2019-06-24 Blombery, P; Birkinshaw, RW; Nguyen, T; Gong, JN; Thompson, ER; Xu, Z; Westerman, DA; Czabotar, PE; Dickinson, M; Huang, DCS; Seymour, JF; Roberts, AW
Link to Publisher's Version
Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia Haematologica - 2019-04 Kenealy, M; Hertzberg, M; Benson, W; Taylor, K; Cunningham, I; Stevenson, W; Hiwase, D; Eek, R; Zantomio, D; Jong, S; Wall, M; Blombery, P; Gerber, T; Debrincat, M; Zannino, D; Seymour, JF
Link to Open Access at Publisher's Site
Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia Cancer Discovery - 2019-03 Blombery, P; Anderson, MA; Gong, JN; Thijssen, R; Birkinshaw, RW; Thompson, ER; Teh, CE; Nguyen, T; Xu, Z; Flensburg, C; Lew, TE; Majewski, IJ; Gray, DHD; Westerman, DA; Tam, CS; Seymour, JF; Czabotar, PE; Huang, DCS; Roberts, AW
Link to Publisher's Version
Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma Nature Medicine - 2018-11-19 Agarwal, R; Chan, YC; Tam, CS; Hunter, T; Vassiliadis, D; Teh, CE; Thijssen, R; Yeh, P; Wong, SQ; Ftouni, S; Lam, EYN; Anderson, MA; Pott, C; Gilan, O; Bell, CC; Knezevic, K; Blombery, P; Rayeroux, K; Zordan, A; Li, J; Huang, DCS; Wall, M; Seymour, JF; Gray, DHD; Roberts, AW; Dawson, MA; Dawson, SJ
Link to Publisher's Version
Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Clinical Cancer Research - 2018-09 Davids, MS; Hallek, M; Wierda, W; Roberts, AW; Stilgenbauer, S; Jones, JA; Gerecitano, JF; Kim, SY; Potluri, J; Busman, T; Best, A; Verdugo, ME; Cerri, E; Desai, M; Hillmen, P; Seymour, JF
Link to Publisher's Version
Venetoclax for patientswWith Chronic Lymphocytic Leukemia With 17p deletion: results from the full population of a phase II pivotal trial Journal of Clinical Oncology - 2018-07-01 Stilgenbauer, S; Eichhorst, B; Schetelig, J; Hillmen, P; Seymour, JF; Coutre, S; Jurczak, W; Mulligan, SP; Schuh, A; Assouline, S; Wendtner, CM; Roberts, AW; Davids, MS; Bloehdorn, J; Munir, T; Bottcher, S; Zhou, L; Salem, AH; Desai, M; Chyla, B; Arzt, J; Kim, SY; Verdugo, M; Gordon, G; Hallek, M; Wierda, WG
Link to Publisher's Version
JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias Genes & Development - 2018-06-01 Kim, SK; Knight, DA; Jones, LR; Vervoort, S; Ng, AP; Seymour, JF; Bradner, JE; Waibel, M; Kats, L; Johnstone, RW
Link to Open Access at Publisher's Site
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma New England Journal of Medicine - 2018-03-29 Tam, CS; Anderson, MA; Pott, C; Agarwal, R; Handunnetti, S; Hicks, RJ; Burbury, K; Turner, G; Di Iulio, J; Bressel, M; Westerman, D; Lade, S; Dreyling, M; Dawson, SJ; Dawson, MA; Seymour, JF; Roberts, AW
Link to Publisher's Version
Idarubicin dose escalation during consolidation therapy for adult acute myeloid leukemia J Clin Oncol - 2017-05-20 Bradstock, KF; Link, E; Di Iulio, J; Szer, J; Marlton, P; Wei, AH; Enno, A; Schwarer, A; Lewis, ID; D'Rozario, J; Coyle, L; Cull, G; Campbell, P; Leahy, MF; Hahn, U; Cannell, P; Tiley, C; Lowenthal, RM; Moore, J; Cartwright, K; Cunningham, I; Taper, J; Grigg, A; Roberts, AW; Benson, W; Hertzberg, M; Deveridge, S; Rowlings, P; Mills, AK; Gill, D; Bardy, P; CAMPBELL, L; Seymour, JF; Australasian Leukaemia Lymphoma Group,
Link to Publisher's Version
Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia Nat Commun - 2017-03-17 Yeh, P; Hunter, T; Sinha, D; Ftouni, S; Wallach, E; Jiang, D; Chan, YC; Wong, SQ; Silva, MJ; Vedururu, R; Doig, K; Lam, E; Arnau, GM; Semple, T; Wall, M; Zivanovic, A; Agarwal, R; Petrone, P; Jones, K; Westerman, D; Blombery, P; Seymour, JF; Papenfuss, AT; Dawson, MA; Tam, CS; Dawson, SJ
Link to Publisher's Version
Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma J Clin Oncol - 2017-03-10 Davids, MS; Roberts, AW; Seymour, JF; Pagel, JM; Kahl, BS; Wierda, WG; Puvvada, S; Kipps, TJ; Anderson, MA; Salem, AH; Dunbar, M; Zhu, M; Peale, F; Ross, JA; Gressick, L; Desai, M; Kim, SY; Verdugo, M; Humerickhouse, RA; Gordon, GB; Gerecitano, JF
Link to Publisher's Version Link to PubMed Central Version
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study Lancet Oncol - 2017-02 Seymour, JF; Ma, S; Brander, DM; Choi, MY; Barrientos, J; Davids, MS; Anderson, MA; Beaven, AW; Rosen, ST; Tam, CS; Prine, B; Agarwal, SK; Munasinghe, W; Zhu, M; Lash, LL; Desai, M; Cerri, E; Verdugo, M; Kim, SY; Humerickhouse, RA; Gordon, GB; Kipps, TJ; Roberts, AW
Link to Publisher's Version Link to PubMed Central Version
Venetoclax in patients with previously treated chronic lymphocytic leukemia Clinical Cancer Research - 2017-01-18 Roberts, AW; Stilgenbauer, S; Seymour, JF; Huang, DC
Link to Publisher's Version
Clinico-pathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax Blood - 2017 Anderson, MA; Tam, C; Lew, TE; Juneja, S; Juneja, M; Westerman, D; Wall, M; Lade, S; Gorelik, A; Huang, DCS; Seymour, JF; Roberts, AW
Link to Publisher's Version
Transformed lymphoma Hematol Oncol Clin North Am - 2016-12 Anderson, MA; Blombery, P; Seymour, JF
Link to Publisher's Version
The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53 independent mechanism Blood - 2016-04-11 Anderson, MA; Deng, J; Seymour, JF; Tam, C; Kim, SY; Fein, J; Yu, L; Brown, JR; Westerman, D; Si, EG; Majewski, IJ; Segal, D; Heitner Enschede, SL; Huang, DC; Davids, MS; Letai, A; Roberts, AW
Link to Publisher's Version Link to PubMed Central Version
Progress in BCL2 inhibition for patients with chronic lymphocytic leukemia Semin Oncol - 2016-04 Tam, CS; Seymour, JF; Roberts, AW
Link to Publisher's Version

An error has occurred. This application may no longer respond until reloaded. Reload 🗙